Regenerative Medicine Landscape Market

The competitive landscape for regenerative medicine continues to evolve. As private sector investment in active players continues, efforts by governments in the US and EU are helping to advance the field, including the recent passage of the 21st Century Cures Act in the US, providing a special status pathway for regenerative medicine advanced therapies. Over the past five years, deal-making has occurred at a rapid pace, and regenerative medicine-focused biotech companies have drawn top dollar in both partnering and mergers and acquisitions.

The regenerative medicine market is undergoing many changes, and involves several modalities, from cell and gene therapies, to gene editing technologies, and tissue regeneration products. Devices, including tissue engineering products, currently dominate the marketed regenerative medicine portfolio, but this is expected to change as the pipeline for pharmaceuticals, namely cell and gene therapies, numbers in the thousands and includes a strong Phase II program as well as many novel candidates awaiting approval.

For the purposes of this report, the regenerative medicine market is broadly divided into device and therapy categories in the Key Company Players in Regenerative Medicine, Regenerative Medicine Approved Product Trends, and Regenerative Medicine Pipeline Trends chapters, followed by further market segmentation. The regenerative medicine device category includes biologic bone regenerative and repair devices, biologic soft tissue regeneration and repair devices, musculoskeletal scaffolds, and other tissue engineering products. The regenerative medicine therapy category covers cell therapies, gene therapies, and gene editing.

Exclusive Sample Report @ https://www.reportsworldwide.com/enquiry?report_id=41341

Report Contents

CONTENTS

EXECUTIVE SUMMARY

THE REGENERATIVE MEDICINE LANDSCAPE
Both the US and EU have specialized pathways for regenerative medicines
Modalities in regenerative medicine
Bibliography

KEY COMPANY PLAYERS IN REGENERATIVE MEDICINE
Across the marketed product portfolio, many players are emerging as leaders
Active developers in the pipeline include large and small companies
Bibliography

REGENERATIVE MEDICINE APPROVED PRODUCT TRENDS
Marketed products in regenerative medicine are dominated by devices
Bone grafts and cell therapies account for the largest concentration of marketed regenerative medicines
Musculoskeletal conditions lead the indications for approved or launched regenerative medicines
Availability of launched regenerative medicine products varies between therapies and devices
Bibliography

REGENERATIVE MEDICINE PIPELINE TRENDS
The pipeline is being driven by cell and gene therapies
Devices in development span multiple product types, but tend to focus on bone fractures and defects
Early-stage research is supporting regenerative medicine therapies
Noteworthy regenerative medicines are on the brink of approval
In vivo gene therapies represent nearly one-third of the regenerative medicine pharmaceuticals pipeline
The majority of regenerative medicines are in development for cancer or rare diseases
The regenerative medicine product type employed varies across therapy areas
Bibliography

DEAL-MAKING TRENDS IN REGENERATIVE MEDICINE
Regenerative medicine financing trends
Regenerative medicine mergers and acquisitions trends
Regenerative medicine alliances trends
Bibliography

TOC Continued……!

Ask to Expertise @ https://www.reportsworldwide.com/enquiry?report_id=41341

About US:

Reportsworldwide.com is a one stop shop for all market intelligence needs. Our database of market research reports provides in depth coverage of 12 top industry verticals worldwide. We help you meet your market intelligence needs by mapping it with our database of market research reports including.

Contact Us:

Email: [email protected]

Phone: +1 (617) 398-1947